{
    "nctId": "NCT00659373",
    "briefTitle": "Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02",
    "officialTitle": "Investigating Cognitive Function for Patients Participating in the SOFT Trial in Selected Centers",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Fatigue, Sleep Disorders",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "N/A",
    "enrollmentCount": 86,
    "primaryOutcomeMeasure": "Change in Cognitive Function Over 1 Year in Premenopausal Breast Cancer Patients Who Receive Adjuvant Tamoxifen (T) Alone Against Those Receive Adjuvant Tamoxifen (T+OFS) or Exemestane (E+OFS) With Ovarian Function Suppression (OFS)",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed breast cancer\n\n  * Completely resected disease\n* Registered for clinical trial IBCSG-2402, but not yet started protocol hormonal therapy\n\n  * Has not yet received any of the following adjuvant endocrine therapy, either before or after registration on IBCSG-2402:\n\n    * Tamoxifen, exemestane, or gonadotropin-releasing hormone (GnRH) agonist\n    * Ovarian irradiation\n    * Bilateral oophorectomy\n* Hormone receptor status:\n\n  * Estrogen and/or progesterone receptor positive\n\n    * Each tumor must be hormone receptor positive\n\nPATIENT CHARACTERISTICS:\n\n* Premenopausal\n* Can speak and read the local language(s) fluently\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}